Bristol-Myers Squibb Co. and Nektar Therapeutics executed a global strategic development and commercialization collaboration for Nektar's lead immuno-oncology program, NKTR-214. Under the collaboration, the companies will jointly develop and commercialize NKTR-214 in combination with BMS's Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) in more than 20 indications across nine tumor types, as well as potential combinations with other anti-cancer agents from either of the respective companies and/or third parties.
The United Kingdom's National Institute for Health and Care Excellence has published a Final Appraisal Determination recommending FOTIVDA (tivozanib) for the first line treatment of adult patients with advanced renal cell carcinoma.
FDA approved abiraterone acetate (Zytiga) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). The drug is sponsored by Janssen Biotech Inc.
Foundation Medicine Inc. and the European Organisation for Research and Treatment of Cancer announced a collaboration in which Foundation Medicine's comprehensive genomic profiling tests will be used to inform patient eligibility for oncology clinical trials through the EORTC's Screening Patients for Efficient Clinical Trial Access program, which is a pan-European network built by the EORTC with key institutions collaborating to provide efficient access for patients to molecularly driven clinical trials.
ANGLE plc has signed an agreement with Abbott in which Abbott will supply ANGLE with its proprietary PathVysion HER-2 DNA FISH Probe kits for ANGLE's ANG-002 FDA study for FISH (fluorescence in situ hybridization) analysis of circulating tumor cells in the form of a research grant.
FDA has approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc.) a radiolabeled somatostatin analog, for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors in adults.
Amgen said the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a label variation for Kyprolis (carfilzomib) to include updated overall survival data from the phase III head-to-head ENDEAVOR trial in patients with relapsed or refractory multiple myeloma (Kyprolis and dexamethasone versus Velcade [bortezomib] and dexamethasone).
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, announced a new clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca's durvalumab, a human monoclonal antibody directed against programmed death-ligand 1, in combination with SNDX-6352, Syndax's monoclonal antibody inhibitor of Colony-StimulatingFactor 1 Receptor, across a variety of solid tumors.
Foundation Medicine Inc. said the company has entered into a broad partnership with Pfizer Inc.
FDA has approved the supplemental New Drug Application to add overall survival data from the phase III head-to-head ENDEAVOR trial to the Prescribing Information for Kyprolis (carfilzomib).
